Document is current
Any future updates will be listed below
-
Authors
Dobersalske, Celia https://orcid.org/0000-0003-4233-102X
Rauschenbach, Laurèl https://orcid.org/0000-0001-8348-4298
Hua, Yichao https://orcid.org/0000-0002-1695-172X
Berliner, Christoph https://orcid.org/0000-0001-9201-8803
Steinbach, Anita
Grüneboom, Anika https://orcid.org/0000-0002-7928-5613
Kokkaliaris, Konstantinos D.
Heiland, Dieter H. https://orcid.org/0000-0002-9258-3033
Berger, Pia https://orcid.org/0000-0003-1453-3193
Langer, Sarah https://orcid.org/0000-0003-0286-7233
Tan, Chin L. https://orcid.org/0000-0002-2529-1030
Stenzel, Martin
Landolsi, Somaya
Weber, Flora https://orcid.org/0000-0001-6407-8542
Darkwah Oppong, Marvin
Werner, Rudolf A.
Gull, Hanah
Schröder, Thomas
Linsenmann, Thomas https://orcid.org/0000-0001-6763-8680
Buck, Andreas K.
Gunzer, Matthias https://orcid.org/0000-0002-5534-6055
Stuschke, Martin
Keyvani, Kathy https://orcid.org/0000-0003-2558-5159
Forsting, Michael
Glas, Martin
Kipnis, Jonathan https://orcid.org/0000-0002-3714-517X
Steindler, Dennis A.
Reinhardt, Hans Christian
Green, Edward W. https://orcid.org/0000-0003-1922-2298
Platten, Michael https://orcid.org/0000-0002-4746-887X
Tasdogan, Alpaslan https://orcid.org/0000-0003-2543-852X
Herrmann, Ken
Rambow, Florian
Cima, Igor
Sure, Ulrich https://orcid.org/0000-0002-9073-1821
Scheffler, Björn https://orcid.org/0000-0001-8316-6556
- License Information
-
More Information
Article History
Received: 26 June 2023
Accepted: 25 June 2024
First Online: 31 July 2024
Competing interests
: C.D., L.R., D.A.S., F.R., I.C., U.S. and B.S. are inventors on a patent application related to cellular data of this study (EP24160641.7). C.L.T., M.P. and E.W.G. are inventors on a patent application describing the identification of tumor-reactive TCRs (WO 2022/200456). M.D.O. receives consulting fees from Brainlab AG and no support was provided for this study or data presented here. D.A.S. is a cofounder of Round Table Research, focused on oncology and degenerative diseases, with currently unrelated technologies and no support provided for this study or data presented here. R.A.W. has received speaker honoraria from Novartis/AAA and PentixaPharm, reports advisory board work for Novartis/AAA and Bayer and is involved in <sup>68</sup>Ga-Pentixafor PET Imaging in PAN Cancer (FORPAN; sponsored and planned by PentixaPharm). A.K.B. has received speaker honoraria from Novartis/AAA and PentixaPharm, is a board member/officer/trustee for PentixaPharm and is involved in <sup>68</sup>Ga-Pentixafor PET Imaging in PAN Cancer (FORPAN; sponsored and planned by PentixaPharm). H.C.R. received consulting and lecture fees from AbbVie, AstraZeneca, Roche, Janssen-Cilag, Novartis, Vertex and Merck; has received research funding from Gilead and AstraZeneca; and is a cofounder of CDL Therapeutics GmbH. M.P. and E.W.G. are founders of Tcelltech GmbH. B.S. reports grants from BMWK and DKFZ-Bayer Joint Alliance outside the submitted work. Additionally, B.S. has a patent for peripheral zone tumor cells, methods for their preparation and use issued (EP2324111, AU 2009291203 and USPTO 9,103,819). The other authors declare no competing interests.
